Bavarian Nordic A/S (OTCMKTS:BVNRY) Short Interest Update

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) was the target of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 100 shares, a drop of 98.1% from the March 15th total of 5,200 shares. Based on an average daily volume of 5,200 shares, the short-interest ratio is presently 0.0 days.

Bavarian Nordic A/S Stock Performance

BVNRY stock traded down $0.07 during midday trading on Wednesday, reaching $7.18. The company's stock had a trading volume of 582 shares, compared to its average volume of 6,238. The stock has a fifty day simple moving average of $7.70 and a two-hundred day simple moving average of $7.61. Bavarian Nordic A/S has a 1 year low of $5.95 and a 1 year high of $10.65. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of 7.56 and a beta of 1.50.

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) last announced its quarterly earnings results on Wednesday, March 6th. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.44 by $0.12. The firm had revenue of $353.27 million for the quarter, compared to analyst estimates of $340.71 million. Bavarian Nordic A/S had a return on equity of 0.07% and a net margin of 20.80%. As a group, analysts forecast that Bavarian Nordic A/S will post 0.57 EPS for the current fiscal year.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.